Diabetes Crash Course: The Outpatient Setting Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University October 7, 2008

Slides:



Advertisements
Similar presentations
Oral Hypoglycemic Drugs And Classifications
Advertisements

Update on the Pharmacological Treatments for Diabetes Mellitus
Canadian Diabetes Association Clinical Practice Guidelines Pharmacologic Management of Type 2 Diabetes Chapter 13 William Harper, Maureen Clement, Ronald.
Diabetes (abridged!). Who needs screening for DM? Age >45 Obese – BMI >25 1 st degree relative with DM Racial groups: –African American –Hispanic American.
Krisa Christian MD. Diabetes 1 in every 14 Americans has diabetes The disease accounts for 200,000 deaths, 82,000 amputations, 44,400 cases of ESRD, and.
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs.
Glycogen Metabolism Storage and Mobilization of Glucose NUTR 543 – Advanced Nutritional Biochemistry David L. Gee, PhD Professor of Food Science and Nutrition.
Updates in Diabetes Management Kim Tartaglia, MD August 22, 2007.
Glycemic Control Medications. Sulfonylureas (2 nd generation) Dose Size Dose/day (mg) Peak (hrs) Dose Interval Common side effects Glyburide (Micronase®,
Oral Medications to Treat Type 2 Diabetes
Combination Therapy in Type 2 Diabetes
Barriers to Diabetes Control Mark E. Molitch, MD.
Chapter 36 Agents Used to Treat Hyperglycemia and Hypoglycemia.
Hyperglycemia Management – Medication Therapy
Insulin therapy.
Diabetes Treatments: Options for Insulin Delivery Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute.
Diabetes: An Overview Christine Rubie MS, RD, LD.
LONG TERM BENEFITS OF ORAL AGENTS
CHAPTER 32 Antidiabetic Drugs
DIABETES MELLLITUS Strategies for Achieving Control in an Office Setting.
DIABETES MELLITUS THERAPY. Nutrition Therapy  Weight loss frequently is a primary goal of nutrition therapy because 80% to 90% of people with type II.
Diabetes Mellitus Oral Hypoglycemic Agents Dr. A. ghanei endocrinologist.
INSULIN THERAPY IN TYPE 1 DIABETES
Agents Used to Treat Hyperglycemia and Hypoglycemia
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
oral hypoglycemic agents
Oral Hypoglycemic Drugs
XIV. PANCREATIC HORMONES 1.Insulin - secreted by ß-cells 2.Glucagon - secreted by  -cells 3.Both hormones regulate blood glucose levels A. Hormones Diabetes.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 31 Antidiabetic Drugs.
Glucoregulatory Drugs Ways To Control Blood Glucose In Diabetic Patients.
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 3 of 3.
Chronic Disease Management- Diabetes. 43 year old male presents with one month history of feeling very thirsty and hungry. Urinating 5 times every night.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
CLINICAL UPDATES: MANAGEMENT OF DIABETES MELLITUS.
Managing Type 2 Diabetes: Review of Recent Guidelines Gina Ryan, Pharm.D., BCPS, CDE Clinical Associate Professor Mercer University College of Pharmacy.
DIABETES MELLITUS THOMAS MILLIGAN, DO OSU-COM FAMILY MEDICINE.
Oral hypoglycemic drugs
Diabetes- Chapter 49.
The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes
Diabetes Mellitus Overview and Treatments
Diabetes- Chapter 43 Revised 11/10. Types of Diabetes Type 1 — insulin- dependent diabetes mellitus (IDDM) Insulin produced in insufficient amount Requires.
Oral hypoglycemic drugs
1 Drugs used for Diabetes Mellitus. 2 Introduction There are 2 types of diabetes mellitus: There are 2 types of diabetes mellitus: Type 1: Insulin-dependent.
Dr. Laila M. Matalqah Ph.D. Pharmacology. Classifications Of Diabetes Type 1 diabetes (insulin-dependent diabetes mellitus): TT with insulin injection.
Technology to Assist with Diabetes Care February 4, 2011 Margaret Pochay RD CDE.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
GO! Diabetes Residency Train the Trainer Program.
Focus on Diabetes Mellitus NUR 171. How insulin works dia2.us.elsevierhealth.com/ondemand/archieAnimations/423.flv.
Diabetes mellitus. Fasting venous plasma glucose ≥ 7mmol/l(126mg/dl) Metabolic disorder, hyperglycemia, abnormality in C.H,fat, protein metabolism. Defect.
Dr. Mansour Alzahrani. متى اكتشف داء السكري؟ داء السكري في الحضارة الهندية والصينية القديمة اسهامات علماء المسلمين في داء السكري.
Diabetes Mellitus Pharmacology
Oral hypoGLYCEMICS.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
DIABETES Shantana Jones Clinical Seminar II. Prevalence  25.8 million children and adults have diabetes  Diagnosed: 18.8 million people  Undiagnosed:
A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clerk 陳威任.
Medications Used in the Treatment of Diabetes Mellitus
Objectives Review factors for best therapeutic approach for appropriate pharmacologic choices for diabetes management Review cost implications for.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
Oral hypoglycemic drugs
Diabetes Medications in the Top 200
Drugs for Diabetes Mellitus
Diabetes Jessica Tagerman PharmD
به نام خدا دارو درمانی دیابت
Oral Hypoglycemic Drugs
oral hypoglycemic agents
Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs
DM management Dr.Duaa Hiasat.
DM management Dr.Duaa Hiasat.
Oral hypoglycemics Jennifer R Marks, MD.
Presentation transcript:

Diabetes Crash Course: The Outpatient Setting Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University October 7, 2008

Objectives Upon completion of this crash course, clerkship students will be able to: Differentiate characteristics of Type 1 and Type 2 diabetes mellitus Differentiate characteristics of Type 1 and Type 2 diabetes mellitus Describe the literature supporting intensive therapy for treating hyperglycemia Describe the literature supporting intensive therapy for treating hyperglycemia State goals of therapy for patients with DM State goals of therapy for patients with DM Organize antidiabetic agents into groups based on place in DM pharmacotherapy Organize antidiabetic agents into groups based on place in DM pharmacotherapy Recommend an appropriate medication regimen for DM based on patient-specific parameters Recommend an appropriate medication regimen for DM based on patient-specific parameters

Major Classifications Type 1 Diabetes – results from β-cell destruction, usually leading to absolute insulin deficiency Type 1 Diabetes – results from β-cell destruction, usually leading to absolute insulin deficiency Type 2 Diabetes – results from a progressive insulin secretory defect on the background of insulin resistance Type 2 Diabetes – results from a progressive insulin secretory defect on the background of insulin resistance Gestational Diabetes – diagnosed during pregnancy Gestational Diabetes – diagnosed during pregnancy

Clinical Trials DCCT: Type 1 patients DCCT: Type 1 patients –Improved glycemic control reduces the risk and slow the progression of microvascular disease EDIC: Type 1 patients EDIC: Type 1 patients –Improved glycemic control protects against the occurrence of macrovascular disease UKPDS: Type 2 patients UKPDS: Type 2 patients –Strict glycemic control results in a reduction in risk of microvascular disease

Decrease in A1C Secondary analysis revealed that a 1% decrease in A1C was associated with: Secondary analysis revealed that a 1% decrease in A1C was associated with: –35% reduction in microvascular endpoints –18% reduction in MI –17% reduction in all-cause mortality

Glycemic Goals A1C is primary target for glycemic control A1C is primary target for glycemic control A1C goal for patients in general is 7% A1C goal for patients in general is 7% A1C goal for the individual patient is as close to < 6% as possible without significant hypoglycemia A1C goal for the individual patient is as close to < 6% as possible without significant hypoglycemia

Antidiabetic Medications

Patient Case

Biguanides Example: Metformin (Glucophage) Example: Metformin (Glucophage) –500 mg daily or BID, Max: 2550 mg/day Lowers A1c 1.5-2%  FIRST LINE AGENT Lowers A1c 1.5-2%  FIRST LINE AGENT MOA: Decreases hepatic glucose production, increase response to insulin MOA: Decreases hepatic glucose production, increase response to insulin Contraindications Contraindications –SCr > 1.5 (males) or 1.4 (females) –Acute/chronic metabolic acidosis –HF requiring treatment

Biguanides (cont) Adverse Effects Adverse Effects –GI: Diarrhea, flatulence, nausea –Metallic taste –Lactic acidosis Monitoring Monitoring –Therapeutic: A1c, FPG –AE: SCr (therapy initiation and annually), BMP, intolerance Bottom Line: Usually first choice for Type II patients unless contraindicated Bottom Line: Usually first choice for Type II patients unless contraindicated

Sulfonylureas Examples: Examples: –Glipizide (Glucotrol) 5 mg daily before breakfast, Clinical max: 20 mg daily –Glyburide (DiaBeta, Micronase) –Glimepiride (Amaryl) Lower A1c 1.5-2%  FIRST LINE AGENT Lower A1c 1.5-2%  FIRST LINE AGENT MOA: Increase insulin secretion MOA: Increase insulin secretion Contraindications: Hypersensitivity (sulfa) Contraindications: Hypersensitivity (sulfa)

Sulfonylureas (cont) Adverse Effects Adverse Effects –Hypoglycemia –Some weight gain –Allergic skin reactions / photosensitivity Monitoring Monitoring –Therapeutic: A1c, FBG –AE: FBG Bottom Line: Also used near initiation of therapy Bottom Line: Also used near initiation of therapy

Thiazolidinediones Examples: Examples: –Pioglitazone (Actos) 15 mg daily, Max 45 mg daily –Rosiglitazone (Avandia) Lower A1c 1.0%  Alternative agent Lower A1c 1.0%  Alternative agent MOA: inhibit PPAR-gamma (improves cellular response to insulin) MOA: inhibit PPAR-gamma (improves cellular response to insulin) Contraindications: CHF (also macular edema, risk for MI) Contraindications: CHF (also macular edema, risk for MI)

TZDs (cont) Adverse Effects Adverse Effects –Hepatotoxicity (troglitazone pulled from market) –Exacerbation of CHF –Macular edema Monitoring Monitoring –Therapeutic: A1c, FBG –AEs: LFTs (baseline, periodically, d/c if >3 X ULN), CHF sxs, visual disturbances Bottom Line: Use only if near A1c goal Bottom Line: Use only if near A1c goal

Alpha-Glucosidase Inhibitors Examples: Examples: –Acarbose (Precose) 25 mg mins AC, Max 300 mg daily –Miglitol (Glyset) Lower A1c < 1.0%  Special niche only Lower A1c < 1.0%  Special niche only MOA: inhibit intestinal alpha-glucosidase MOA: inhibit intestinal alpha-glucosidase Contraindications: DKA, IBD, colonic ulceration, intestinal obstruction Contraindications: DKA, IBD, colonic ulceration, intestinal obstruction

AGIs (cont) Adverse effects Adverse effects –GI: flatulence, diarrhea, abdominal pain/cramps –Rash –Increased LFTs Monitoring Monitoring –Therapeutic: A1c, FBGs, post-prandial glucose –AE: LFTs, s/sxs rash, intolerance Bottom Line: Only for lowering PPG Bottom Line: Only for lowering PPG

Meglitinides Examples: Examples: –Repaglinide (Prandin) 4 mg TID with meals, Max 12 mg TID –Nateglinide (Starlix) Lower A1c 0.8-1%  Special niche only Lower A1c 0.8-1%  Special niche only MOA: Stimulate insulin secretion MOA: Stimulate insulin secretion Contraindications: Really, none Contraindications: Really, none

Meglitinides (cont) Adverse Effects Adverse Effects –Hypoglycemia (less than SUs) –Weight gain Monitoring Monitoring –Therapeutic: A1c, FBGs –AE: FBG Bottom Line: Alternative for pts unable to take sulfonylurea Bottom Line: Alternative for pts unable to take sulfonylurea

GLP-1 System Drugs First example: First example: –Exenatide (Byetta) 5 mcg SQ BID, Max 10 mcg BID Lowers A1c 0.8-1%  Alternative agent Lowers A1c 0.8-1%  Alternative agent MOA: Synthetic GLP-1 MOA: Synthetic GLP-1 Contraindications: Really, none Contraindications: Really, none

GLP-1 System Drugs (cont) Adverse Effects Adverse Effects –Nausea (dose-dependant) –Hypoglycemia –Pancreatitis Monitoring Monitoring –Therapeutic: A1c, FBGs –AEs: FBGs Bottom Line: New drug, place in therapy TBD Bottom Line: New drug, place in therapy TBD

GLP-1 System Drugs (cont) Second example: Second example: –Sitagliptin (Januvia) 100 mg daily (lower doses per renal function) Lowers A1c  Alternative agent Lowers A1c  Alternative agent MOA: inhibits DDP-IV MOA: inhibits DDP-IV Contraindications: Really, none Contraindications: Really, none

GLP-1 System Drugs (cont) Adverse Effects Adverse Effects –Very little HA Monitoring Monitoring –Therapeutic: A1c, FBGs Bottom Line: New drug, place in therapy TBD Bottom Line: New drug, place in therapy TBD

Amylin Analogs Example: Example: –Pramlintide (Symlin) 60 mcg before meals, Max 120 mcg Lowers A1c  Not very good, used in combination with insulin Lowers A1c  Not very good, used in combination with insulin MOA: Synthetic analog of amylin MOA: Synthetic analog of amylin Contraindications: Really, none Contraindications: Really, none

Amylin Analogs (cont) Adverse effects Adverse effects –NV, anorexia (decrease over time, delay dose increase until nausea resolves) –Hypoglycemia Monitoring Monitoring –Therapeutic: A1c, FBGs –AEs: FBGs, sxs NV Bottom Line: Utility? Only agent besides insulin for Type 1 patients Bottom Line: Utility? Only agent besides insulin for Type 1 patients

Comparison Agent FBG ↓ (mg/dL) A1C ↓ Hypoglycemia Weight Effects Sulfonylureas YesGain Metformin No- α-glucosidase inhibitors 10-25<1.0No- Thiazolidinediones NoGain Meglitinides YesGain Exenatide NoLoss Sitagliptin No- Pramlintide YesLoss Insulin↓↓>2.0YesGain

Insulins Rapid-acting Peak ~ 1 hour Rapid-acting Peak ~ 1 hour –Lispro (Humalog), Aspart (Novolog), Apidra (Glulysine) Fast-acting Peak ~ 3 hours Fast-acting Peak ~ 3 hours –Regular (Humulin R, Novolin R) Intermediate-acting Peak ~ 8 hours Intermediate-acting Peak ~ 8 hours –NPH (Humulin N, Novolin N) Long-acting Long-acting –Glargine (Lantus), Detemir (Levimir)

AS Case (cont) DateBreakfastLunchDinnerBedtime 2/ / / / / / / / Lantus 34 units QHS and Humalog 6 units before meals